Table 1 –
Baseline demographic, clinical, and laboratory characteristics of the 217,143 patients with chronic liver diseases with and without cirrhosis included in the analysis
| Non-Cirrhosis / Negative | Non-Cirrhosis / Positive | Cirrhosis / Negative | Cirrhosis / Positive | |
|---|---|---|---|---|
| (n = 129,097) | (n = 25,844) | (n = 54,065) | (n = 8,137) | |
| Female | 67,488 (52) | 13,726 (53) | 23,537 (44) | 3,539 (43) |
| Age (years) | 54 (42–63) | 53 (41–63) | 60 (50–67) | 61 (51–68) |
| 18–29 | 8,665 (7) | 1,802 (7) | 1,418 (3) | 206 (3) |
| 30–49 | 42,562 (33) | 8,994 (35) | 11,356 (21) | 1,547 (19) |
| 50–64 | 48,882 (38) | 9,683 (37) | 22,891 (42) | 3,352 (41) |
| 65+ | 28,988 (22) | 5,365 (21) | 18,400 (34) | 3,032 (37) |
| Race/Ethnicity | ||||
| White | 80,918 (63) | 13,978 (54) | 35,943 (66) | 4,585 (56) |
| Black/African-American | 19,416 (15) | 3,917 (15) | 8,766 (16) | 1,579 (19) |
| Hispanic | 16,185 (13) | 5,240 (20) | 5,163 (10) | 1,232 (15) |
| Asian | 4,466 (3) | 940 (4) | 1,137 (2) | 180 (2) |
| Unknown/Other | 8,112 (6) | 1,769 (7) | 3,056 (6) | 561 (7) |
| Height (cm) # | 170 (163–178) | 170 (162–178) | 170 (162–179) | 170 (163–178) |
| Weight (kg) # | 90 (75–107) | 93 (79–111) | 83 (69–100) | 86 (71–104) |
| BMI (kg/m2) # | 31 (26–37) | 33 (28–38) | 28 (24–34) | 30 (25–36) |
| Liver Disease Etiology | ||||
| NAFLD | 84,916 (66) | 18,458 (71) | 17,707 (33) | 3,109 (38) |
| Hepatitis C | 28,125 (22) | 4,087 (16) | 10,797 (20) | 1,597 (20) |
| AALD | 8,307 (6) | 1,812 (7) | 18,278 (34) | 2,322 (29) |
| Hepatitis B | 5,372 (4) | 1,139 (4) | 2,183 (4) | 369 (5) |
| Cholestatic | 784 (1) | 87 (0) | 3,240 (6) | 465 (6) |
| Autoimmune | 1,593 (1) | 261 (1) | 1,860 (3) | 275 (3) |
| Charlson Comorbidity Index | 2 (1–4) | 2 (1–4) | 4 (2–7) | 5 (2–8) |
| Region | ||||
| Northeast | 12,381 (10) | 2,457 (10) | 3,556 (7) | 637 (8) |
| Midwest | 19,069 (15) | 4,377 (17) | 9,646 (18) | 1,488 (18) |
| South | 21,656 (17) | 3,550 (14) | 9,377 (17) | 1,109 (14) |
| West | 14,752 (11) | 2,275 (9) | 5,817 (11) | 613 (8) |
| Other | 61,239 (47) | 1,3185 (51) | 25,669 (47) | 4,290 (53) |
| Laboratory Tests # | ||||
| Albumin (g/L) | 4.0 (3.6–4.4) | 3.8 (3.3–4.2) | 3.4 (2.9–4.0) | 3.2 (2.6–3.8) |
| AST (u/L) | 28 (20–47) | 32 (22–52) | 41 (25–74) | 44 (27–78) |
| ALT (u/L) | 31 (19–55) | 37 (22–65) | 29 (18–51) | 32 (20–57) |
| Total Bilirubin (mg/dL) | 0.5 (0.4–0.8) | 0.5 (0.3–0.7) | 0.9 (0.5–2.0) | 0.9 (0.5–2.0) |
| Creatinine (mg/dL) | 0.8 (0.7–1.0) | 0.8 (0.7–1.0) | 0.9 (0.7–1.2) | 0.9 (0.7–1.4) |
| INR | 1.1 (1.0–1.2) | 1.1 (1.0–1.2) | 1.3 (1.1–1.8)) | 1.3 (1.1–1.8) |
| Platelet (109/L) | 241 (190–300) | 240 (184–312) | 172 (105–252) | 166 (100–255) |
| Hemoglobin (g/dL) | 13.0 (11.4–14.3) | 12.9 (11.4–14.2) | 11.3 (9.3–13.2) | 10.8 (9.0–12.7) |
| Neutrophil (109/L) | 4.8 (3.4–6.8) | 4.3 (2.9–6.2) | 4.3 (2.8–6.6) | 4.3 (2.1–13) |
| Lymphocyte (109/L) | 1.8 (1.3–2.5) | 1.5 (1.0–2.1) | 1.3 (0.9–2.0) | 1.2 (0.7–1.7) |
| Neutrophil/Lymphocyte Ratio | 2.8 (1.8–4.6) | 2.5 (1.7–4.2) | 3.1 (1.9–5.5) | 3.7 (2.1–7.3) |
| MELD-NaH * | 10 (8–13) | 10 (8–14) | 16 (11–24) | 17 (12–25) |
Note: Continuous variables are described as medians with interquartile ranges in parathesis, ordinal and categorical variables are described as values with percentages in parathesis.
Height, weight, BMI, and laboratory tests exhibit a range of missingness from 39–88% of the total sample.
MELD-Na scores were calculated for 17,460 patients, which represent 8% of the total sample.
Abbreviations: AALD, alcohol-associated liver disease; AST, aspartate transaminase; ALT, alanine transaminase; BMI, body mass index; INR, international normalized ratio; MELD-Na, Model for End-Stage Liver Disease-Sodium; NAFLD, non-alcoholic fatty liver disease.